Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Ohr Pharmaceutical Inc.
Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration Methodology: Phase III, multicenter, randomized, double-masked, placebo-controlled study conducted over 9 months (Screening/Baseline to Week 36): Patients will be randomly assigned to one of 2 treatment groups in a 1:1 ratio: * Squalamine lactate ophthalmic solution, 0.2% BID + ranibizumab every 4 weeks * Placebo ophthalmic solution BID + monthly ranibizumab every 4 weeks
Age
50–110
Sex
ALL
Healthy volunteers
Not accepted